首页 | 本学科首页   官方微博 | 高级检索  
     

胸段食管鳞状细胞癌不同术后辅助治疗模式疗效分析
引用本文:沈文斌,高红梅,祝淑钗,李腾,李曙光,李幼梅,刘志坤,李娟,苏景伟. 胸段食管鳞状细胞癌不同术后辅助治疗模式疗效分析[J]. 中华放射肿瘤学杂志, 2017, 26(7): 737-743. DOI: 10.3760/cma.j.issn.1004-4221.2017.07.004
作者姓名:沈文斌  高红梅  祝淑钗  李腾  李曙光  李幼梅  刘志坤  李娟  苏景伟
作者单位:050011 石家庄,河北医科大学第四医院放疗科(沈文斌、祝淑钗、李腾、李曙光、李幼梅、刘志坤、李娟、苏景伟);050012石家庄第一医院影像科(高红梅)
摘    要: 目的 比较胸段食管鳞状细胞癌患者术后不同辅助性治疗疗效和预后影响因素分析,为食管癌术后患者寻找最佳治疗方式。 方法 回顾分析2007—2010年间河北医科大学第四医院治疗并入组的 863例胸段食管鳞状细胞癌术后患者资料,其中术后放化疗、术后化疗、术后放疗患者分别为107、635、121例。应用PSM法进行1∶1倾向性匹配后共 261例(87例/组)。Kaplan-Meier法计算OS、DFS并Logrank法检验和单因素分析,Cox模型多因素分析。 结果 1、3、5年样本量分别为123、589、863例。1、3、5年OS和DFS率分别为89.7%、62.1%、51.7%和76.8%、52.1%、44.2%。PSM配对后术后放化疗,术后化疗,术后放疗患者1、3、5年OS和DFS率分别为956%、73.3%、61.1%和85.6%、61.1%、54.4%,78.9%、38.9%、31.3%和67.8%、27.8%、20.0%,92.2%、55.6%、44.4%和67.8%、44.4%、36.7%(P均=0.000)。多因素分析结果显示食管病变炎性黏连程度、pTNM分期和阳性淋巴结个数为PSM法配对后患者OS影响因素(P=0.002、0.000、0.007);饮酒史、pTNM分期和治疗模式为DFS影响因素(P=0.009、0.000、0.012)。 结论 胸段食管鳞状细胞癌术后患者接受辅助性放(化)疗有较好的疗效,术后辅助性放化疗与术后单纯化疗和放疗相比可明显改善患者的OS和DFS,且为患者DFS的独立影响因素。

关 键 词:食管肿瘤/外科学  食管肿瘤/放射疗法  食管肿瘤/化学疗法  治疗结果  预后  
收稿时间:2016-09-02

Therapeutic efficacy of different adjuvant modalities in thoracic esophageal squamous cell carcinoma
Shen Wenbin,Gao Hongmei,Zhu Shuchai,Li Teng,Li Shuguang,Li Youmei,Liu Zhikun,Li Juan,Su Jingwei. Therapeutic efficacy of different adjuvant modalities in thoracic esophageal squamous cell carcinoma[J]. Chinese Journal of Radiation Oncology, 2017, 26(7): 737-743. DOI: 10.3760/cma.j.issn.1004-4221.2017.07.004
Authors:Shen Wenbin  Gao Hongmei  Zhu Shuchai  Li Teng  Li Shuguang  Li Youmei  Liu Zhikun  Li Juan  Su Jingwei
Affiliation:Department of Radiation Oncology,The Forth Hospital,Hebei Medical University,Shijiazhuang 050011,China (Shen WB,Zhu SC,Li T,Li SG,Li YM,Liu ZK,Su JW,Li J);Department of Radiation,The First Hospital of Shijiazhuang,Shijiazhuang 050011,China;Department of Radiology,First Hospital of Shijiazhuang,Shijiazhuang 050012,China (Gao HM)
Abstract:Objective To evaluation and comparison the curative effect of different adjuvant therapy and prognostic factors with thoracic esophageal squamous cell carcinoma (ESCC) after surgery,and to find the best treatment for them.Methods A total of 863 patients with thoracic ESCC underwent surgery in the fourth hospital of Hebei Medical University,From January 2007 to December 2010,To analyze the influence factors of the patient′s independent prognosis and the effect of postoperative adjuvant therapy on the prognosis of patients.The 1:1, after the tendency of a total of 261 cases were used PSM method (87 cases/group).The Kaplan-Meier method was used to calculate OS,DFS and log-rank test and monovariable analysis,Cox model was used to multivariable analysis.Results The sample size in 1,3,5 was 123,589,863 cases.The 1-,3-,and 5-year overall survival (OS) and disease-free survival (DFS) of all patients were 89.7%,62.1%,51.7% and 76.8%,52.1%,44.2%,respectively.The 1,3,5-years of OS and DFS were 956%,73.3%,61.1% and 85.6%,61.1%,54.4%,78.9%,38.9%,31.3% and 67.8%,27.8%,20.0%,92.2%,55.6%,44.4% and 67.8%,44.4%,36.7%(all P=0.000) among postoperation chemoradiotherapy (POCRT),postoperation chemotherapy (POCT) and postoperation radiotherapy (PORT) after pairing with PSM.The result of COX analysis showed that the degree of inflammatory adhesion,pTNM stage and the number of positive lymph nodes were the independent prognostic factors in patients with OS (P=0.002,0.000,0.007).The history of drinking,pTNM stage and treatment model were the independent prognostic factors of DFS (P=0.009,0.000,0.012).Conclusions Patients with thoracic esophageal squamous cell carcinoma after surgery to receive adjuvant therapy has a good effect,compared with PORT and POCT,POCRT can significantly improve the OS and DFS,and POCRT was the independent prognostic factors of DFS.
Keywords:Esophageal neoplasms/surgery  Esophageal neoplasms/radiotherapy  Esophageal neoplasms/chemotherapy  Treatment outcome  Prognosis
本文献已被 万方数据 等数据库收录!
点击此处可从《中华放射肿瘤学杂志》浏览原始摘要信息
点击此处可从《中华放射肿瘤学杂志》下载全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号